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Abstract
Background: Lennox-Gastaut syndrome (LGS) is a severe form of childhood epilepsy that is
defined by generalized multiple type seizures, slowness of intellectual growth, and a specific EEG
disturbance. Children affected might previously have infantile spasms or underlying brain disorder
but etiology can be idiopathic. In South Africa, the incidence of secondary epilepsy is higher than
what is found in developed countries resulting in higher incidence of the disease. LGS seizures are
often treatment resistant and the long term prognosis is poor.
Report: A twenty six year old female, presented with anterior open bite, macroglossia,
supragingival as well as subgingival calculus. The gingiva was red, swollen and friable and there was
generalized bleeding and localized suppuration. The patient had gingival recession. After
periodontal therapy a remarkable improvement in oral health status was noted.
Conclusion: The clinical findings in LGS included facial deformities, periodontitis and gingival
swellings. Interdisciplinary treatment of these patients is fundamental and oral attention is of
outstanding importance. Non-surgical periodontal therapy was effective in controlling periodontal
disease in the reported case, but prevention of periodontal and dental diseases is preferable for this
high-risk group of patients.
Background and literature review
Lennox-Gastaut syndrome (LGS) is one of the cata-
strophic childhood epilepsies. It is defined by a triad of
symptoms:
- Multiple types of generalized seizures, which are difficult
to control.
- Slowness of intellectual growth, often accompanied by
mental retardation and behavioral problems.
- A specific electroencephalogram (EEG) pattern called a
slow spike-and-wave pattern (< 2.5 Hz), which is present
when the child is awake [1-4].
Seizures most often present between the second and sixth
year of life, however; they can start a little earlier or later.
They rarely start after the age of eight [2,3].
William Lennox described the clinical features of the syn-
drome in 1930s, and then Lennox and Davis reported the
symptomatic triad of the syndrome. Later, Gastaut
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Davis [5,6].
The diagnostic criteria of the syndrome have been refined
by researchers, but the basic characteristics of the syn-
drome remained unchanged since Lennox and Davis [7-
11].
Distinguishing LGS syndrome from other epilepsy syn-
dromes has been challenging as it is characterized by
plethora of underlying causes, multiple types of seizures,
and cognitive impairment. Seizures are classified accord-
ing to the International League Against Epilepsy (ILAE)
classification, and specific epilepsy syndromes of child-
hood are recorded when their essential diagnostic ele-
ments are fulfilled. It is now agreed that a number of
individual syndromes, including LGS, form a spectrum of
childhood epilepsies, each with differentiating criteria
[12-14].
Prevalence
The Lennox-Gastaut syndrome is uncommon but it is very
serious. The mortality rate ranges from 3% to 7% [2,5].
Often the prevalence of LGS is described as a percentage
of childhood epilepsy. The reported prevalence of LGS
varies between studies but it is in the range of 3–10% of
childhood epilepsy, and is more common in males than
females [1-3].
Epilepsy is relatively common, but its prevalence varies
widely affecting approximately 3.4/1000 of the popula-
tion in Japan, 6/1000 in the United States, and 11.2/1000
in Mexico [15,16].
In South Africa, the prevalence of epilepsy (all ages) has
been reported as 10 per 1,000 [17]. In rural South African
children aged 2–9 years the prevalence of epilepsy was
0.73%. Out of the affected, 57.1% didn't receive medica-
tion, and 71.4% had developmental disability. These fig-
ures are slightly higher than those derived from other sub-
Saharan African countries [15].
As LGS constitutes a fraction of childhood epilepsy it is
overall rare. However, it is clinically prominent due to the
frequent and difficult to treat seizures that persist into
adulthood, as well as to the need for continuous medical
attention [1].
Epidemiologic community based studies in the so-called
developed countries revealed that the annual incidence of
LGS in childhood was approximately 2 per 100,000 chil-
dren, and the prevalence of LGS was 0.1–0.28 per 1000 in
Europe [4]. Studies demonstrated that the figures of LGS
are relatively consistent across the developed populations.
For example, in Atlanta, USA, LGS accounts for 4% of
patients with childhood epilepsy, with a reported inci-
dence of 0.26 per 1000 live births [6]. The true incidence
in different populations is not known, due to the disparity
between parameters used to define the disease, as well as
to the variability of the predisposing factors to the disease
among different populations.
Etiology
Etiology of LGS is variable; LGS does not usually run in
families but genetic factors may play a role in the etiology
[2,7]. In 20–50% of cases the child has previously had
infantile spasms with underlying brain disorder (also
known as symptomatic West syndrome) [3,5,7,18,19].
For about one third of the affected children a known cause
cannot be identified. These cases are referred to as cryp-
togenic Lennox-Gastaut syndrome [2,3].
On the other side, many of the children who develop Len-
nox-Gastaut syndrome had a pre-existing brain disorder
or injury. Causes identified include tuberous sclerosis,
congenital infections, hereditary metabolic diseases, brain
malformation, and brain damage (due to birth asphyxia
or other birth injuries, encephalitis, meningitis or head
injuries) [2,3].
These patients tend to have worse prognosis than those of
cryptogenic etiology [2,3]. It was noted, however, that
these potential causative factors are different in different
populations, and that in developing countries LGS was
mainly secondary to trauma and infections [17].
In developing countries, there is a high incidence of pre-
term and abnormal births. During infancy and early child-
hood, meningitis, tuberculosis, neurocysticercosis, and
head trauma are common. This situation is expected to
increase the prevalence of secondary (symptomatic) epi-
lepsy and that of intellectual handicap in the child popu-
lation [17].
In a study of childhood recurrent seizures in Red Cross
memorial hospital in Cape Town, South Africa, 11% suf-
fered from menigities or encephalitis as a precipitating
factor and 55% were intellectually handicapped [20].
Most patients who had both grand mal and myoclonic
seizures suffered from LGS [20].
In another study in Cape Town, It was found that 43% of
childhood epilepsy was symptomatic (secondary) [17].
This figure is even higher than other figures found in stud-
ies conducted predominantly in tropical African countries
[17].Page 2 of 7
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and tuberculosis), and trauma have high prevalence
among the poor of the Western Cape, and it is expected
that these conditions serve as precipitating factors of sec-
ondary epilepsy [17]. On the other hand diagnostic facil-
ities are better in Cape Town than in the rest of the studied
African cities, which is expected to reduce the number of
overlooked cases, resulting in higher figures.
Clinical features
Typically, daily multiple seizure types that occur in LGS
are of wide range, more than that of any other epileptic
syndrome. The major kinds of seizures that usually occur
in LGS are the tonic seizures, which are often nocturnal
[3], the atonic seizures (involuntary losses of muscle tone
that cause drop attacks) or atypical absences (child goes
blank lasting up to a minute) [3]. Additionally, about
60% of children may have prolonged or repeated seizures
very close together. This is called status epilepticus and is
an emergency [5]. Some children also have other types of
seizures, such as myoclonic, partial or tonic-clonic sei-
zures [1,3].
Most children with the Lennox-Gastaut syndrome have a
degree of intellectual impairment and learning disability
that ranges from mild to severe. Behavioral problems and
depression are also common, which can be attributed to
the brain injury, the frequent seizures, the lack of normal
social stimulation or as side effects of AntiEpilepticDrugs
(AEDs) [5,21]. Children with Lennox-Gastaut syndrome
are also more likely to have cerebral palsy, progressive
decline in IQ and progressive gait disturbances [5].
Development of the child is frequently retarded at the
onset of disease, depending on the etiopathogenesis of
the underlying brain disease [14].
The syndrome is also characterized by an interictal
(between-seizures) EEG disturbance called slow spike-
wave pattern (< 2.5 Hz), often accompanied by a burst of
fast rhythms of 10 to 12 Hz at night [1-3].
As a result of all these abnormalities, the child may look
irritable, tired or bored. Many children fail to cope with
school and need institutional care. The child's develop-
ment is rarely normal, and often there is delayed develop-
ment or other forms of epilepsy. The seizures can cause
sudden falls and/or loss of balance, and patients are
advised to wear a helmet to prevent head, face and teeth
injuries.
The effects of LGS on the child and his family require a
team of health care professionals to provide the best sei-
zure control, the highest level of function with the least
side effects, and the maximum quality of life possible for
the child and to direct families to appropriate community
resources. These children and their families need the com-
bined support of services from healthcare workers, car-
egivers, friends, school and social workers as well as
psychologists.
Treatment
LGS seizures are often treatment resistant. Basic treatment
is pharmacological and some children may need more
than one mode of treatment.
Pharmacological treatment consists mainly of one or mul-
tiple antiepileptic drugs (AED's). No single treatment reg-
imen could be considered superior to the others, and
management depends on the response of the patients.
Medical treatment usually starts with valproates (valproic
acid, sodium valproate and valproate semisodium) fol-
lowed by adjunctive therapy with either lamotrigine or
topiramate [5,21].
Controlled clinical trials demonstrated that felbamate was
beneficial in patients with the LGS. However, since fel-
bamate was associated with an increased risk of aplastic
anemia and hepatotoxicity, it is used with extreme caution
and requires regular monitoring of complete blood count
and liver enzymes. It is reserved for children who are
refractory to other therapies [22].
Benzodiazepines, (specifically clonazepam, nitrazepam,
and clobazam) and Phenobarbiturates, are recommended
as third-line choices in cases difficult to control or if stand-
ard treatment is intolerable [5,21].
Surgical options for treatment include
-Vagus nerve stimulation: The procedure involves implan-
tation of a battery-operated device with connecting wires
to the left vagus nerve, which is programmed to deliver a
current at variable frequencies, pulse widths, and times
[23].
-Corpus callosotomy: an operation to cut the corpus cal-
losum (the large bundle of nerve fibres connecting the
two cerebral hemispheres) may be considered in the treat-
ment of LGS [23].
Electrical stimulation of the centromedian thalamic
nucleus (ESCM) was reported as being efficient in the con-
trol of generalized seizures and improvement of quality of
life of the patients. The method involves stereotactic sur-
gical implantation of electrodes to the centromedian
nuclei of the thalamus. Electrodes are stimulated within
set parameters. Patients are scheduled for follow-up visits
for assessment of seizures and neurophysiologic tests.
Main disadvantage was skin erosions that could not be
controlled by plastic surgery procedures [24].Page 3 of 7
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ment. A ketogenic diet is a high fat, low protein, low car-
bohydrates diet that induces ketosis, a state in which there
is an excessive amount of ketones in the body. It is very
effective and is becoming increasingly popular for treat-
ment of LGS [2].
Prognosis
The long term outcome is poor in terms of seizure control
and intellectual development. Catastrophic disorders
such as LGS are associated with morbidity and mortality
[1]. Eighty percent of patients with Lennox-Gastaut syn-
drome continue to have seizures throughout childhood
and into their adult life. The mortality rate ranges from 3
to 7% [2].
To the best of our knowledge this is the first report that
documents the oral clinical and radiographic findings as
well as the response to treatment in a patient with LGS.
Case report
A twenty six year old female with longstanding cryp-
togenic Lennox-Gastaux syndrome was referred to the
department of Oral Medicine and Periodontics, Univer-
sity of the Western Cape, Cape Town, South Africa, com-
plaining of swollen bleeding gums.
The patient was a "longstanding Gastaux-Lennox Syn-
drome case" with occasional generalized seizures, well
controlled on Sodium Valproate, Phenobarbiturates and
Lamotrigine. The patient did not experience any seizures
in the last month before presentation. She was also dia-
betic (type II), well controlled on oral Hydralazine and
Glucophage, and hypertensive controlled on: Atenolol
and Adalat. This medical condition influenced the
patient's abilities and consequently she was dependent on
her family for daily living. Patient had fair intellectual
activity.
Extraoral examination
Patient had course facies, with bimaxillary protrusion,
and her lips were incompetent at rest.
Intraoral examination
The patient had anterior open bite (Figure 1) and mac-
roglossia which made it difficult to perform proper oral
hygiene methods, especially posteriorly, and oral hygiene
status was poor. All teeth were present and the patient had
no restorations. Multiple teeth were carious (smooth sur-
face caries in posterior teeth and pits caries in anterior
teeth).
There were large amounts of supragingival as well as sub-
gingival calculus (Figure 2). The patient reported dental
and periodontal sensitivity at the anterior teeth region.
The gingiva was red, swollen and friable and there was
generalized bleeding and localized suppuration. The
patient had gingival recession labially and lingually/pala-
tally, especially anteriorly (Figure 3). The whole-mouth
mean probing pocket depth was 4.7 mm and 30% of the
periodontal pockets were deeper than 5 mm causing fur-
cation involvement in some posterior teeth. Teeth # 11,
21, 31, 32, 41 and 42 (FDI) were mobile (grade two and
three).
Radiographic examination
An orthopantomograph showed severe horizontal alveo-
lar bone loss, especially anteriorly, and vertical bone loss
around 31 and 36. Spacing of teeth was evident anteriorly.
Multiple proximal radiolucencies were present on poste-
rior teeth (Figure 4).
Inflamed gingiva, and plaque depositsFigur  2
Inflamed gingiva, and plaque deposits.
Anterior open bite and spacing is evidentFigu e 1
Anterior open bite and spacing is evident.Page 4 of 7
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recorded periodontal diagnosis was Generalized Moder-
ate to Severe Chronic Periodontitis associated with sys-
temic disease.
The proposed treatment plan was:
1) Comprehensive oral hygiene instructions and educa-
tion to the patient as well as her family.
2) Extraction of teeth of poor prognosis when general
health conditions allow, and provision of immediate den-
tures.
3) Subgingival scaling using ultrasonic applicators and
hand instruments under local anaesthesia, and the use of
0.2% Chlorehexidine gluconate mouthwash.
4) Root planing of the four quadrants under local anaes-
thesia, with special care to the exposed furcations, and
subgingival irrigation with 1% chlorhexidine solution.
5) Elective gingivoplasty/pocket reduction surgery for
swollen segments with persistent deep pockets.
6) Vitality testing for teeth with questionable pulp vitality,
and restoration of the carious lesions with filling materials
and the edentulous areas by fixed porcelain fused to metal
bridge.
7) Supportive periodontal treatment, with a three month
recall period.
The patient received professional scaling and root planing
distributed over multiple visits, and oral hygiene practices
were emphasized. Three months following the treatment
a remarkable improvement in oral health status was
noted, viewed by absence of gingival inflammation,
reduction of probing pocket depths negating the need for
gingivoplasty or pocket reduction surgery, as well as
absence of calculus or plaque deposits. Teeth # 31, 32, 41,
42 were extracted and an immediate denture was pro-
vided, and the patient was enrolled in supportive perio-
dontal treatment phase consisting of professional tooth
cleaning and motivation of oral hygiene every three
months.
Discussion
Lennox-Gastaut syndrome (LGS) is a catastrophic epilep-
tic encephalopathy that consists of multiple types of gen-
eralized seizures which often vary in their frequency over
a period of time. The syndrome is difficult to treat and
many people receive multiple drugs (polypharmacy)
without achieving satisfactory seizure control [23].
The long-term prognosis is poor; although the epilepsy
often improves with time, complete control of seizures is
rare and with time the mental and behavioural disorders
tend to worsen [23].
In managing patients with LGS the type of seizures, the
level of seizure control, the intellectual activity of the
patient and the possible drug reactions should all be con-
sidered [25].
In a study to determine oral health status and treatment
needs for caries and periodontal lesions, phenytoin
induced gingival hyperplasia and fractures of anterior
teeth, in 12–13 year old epileptic children in South Africa,
it was found that these children were a high risk group and
should be regarded as a priority group for dental treat-
ment. It was recommended to shift oral health programs
from treatment into primary preventive care in these
(high risk) groups [26].
Orthopantomograph showed severe horizontal alveolar bone loss anteriorly, and vertical bone loss around 31 and 36Figure 4
Orthopantomograph showed severe horizontal alveolar 
bone loss anteriorly, and vertical bone loss around 31 and 
36.
Marginal gingivitis and recession palatalyFigure 3
Marginal gingivitis and recession palataly.Page 5 of 7
(page number not for citation purposes)
Head & Face Medicine 2008, 4:9 http://www.head-face-med.com/content/4/1/9The reported case is typical for LGS patients who may
present for dental/oral health care. The patient experi-
enced LGS and she was controlled on three drugs (Polyp-
harmacy) including Phenobarbiturates. A report from
South Africa indicated that more than half of the children
with recurrent seizures in Red Cross memorial hospital in
Cape Town had received Phenobarbiturates at some stage,
and although this drug is not favored in developed coun-
tries because of its adverse effects on behavior and the
higher success rate with carbamazepine, phenytoin, or
valproic acid, it is still widely used in South Africa because
it is cheap and effective [20]. The patient was still experi-
encing occasional generalized seizures. The choice of
medication is usually related to individual tolerance and
efficacy, but it is important to note that all AEDs produce
significant -though variable- side effects, including blood
dyscrasias, anemia, and alteration of hepatic function,
which can deteriorate blood clotting and complicate gen-
eral anesthesia [27]. No such side effects were detected in
the patient.
Thickening of the heel pad and of the calvarium, coarse
facies, congenital anomalies of the face, microstomia and
macroglossia have also been reported. Consistent with the
literature some findings such as macroglossia and coarse
facies were noted in the patient but the exact association
with the syndrome was not disclosed [27,28].
Seizures may occur several times everyday, and patients
suffering drop attacks might have fractures in the head
and face region. Severe cases may interfere with school
and social activities exacerbated by medications especially
phenobarbiturates.
No history of trauma to the face or teeth was recorded but
the patient had poor communication skills and she was
dependant on her family.
Patients on AED's are subject to gingival overgrowth,
mostly associated with using phenytoin. About half of the
patients placed on phenytoin will show evidence of gingi-
val enlargement, usually within 2 to 18 months after start-
ing the medication [25]. The etiology is still unknown, but
there appears to be an increase in the number of fibrob-
lasts in the connective tissues [27]. Valproate is also asso-
ciated with gingival hyperplasia but less than phenytoin
[29]. Polypharmacy itself may predispose the patient to
gingival enlargement [30].
In literature, it was noted that there is a correlation
between poor oral hygiene and the amount of tissue
enlargement [30]. The reported patient had gingival
enlargement which could be a side effect of AED's aggra-
vated by poor oral hygiene, but also it could be compli-
cated by diabetes or hormonal influences.
Management starts by professional cleaning measures that
can reduce the size of the swollen edematous tissue, and
for persisting swollen tissue gingivoplasty/gingivectomy is
performed preferably by radiosurgery to reduce bleeding
at time of operation. The patient was treated only by pro-
fessional scaling and root planing which reduced swell-
ings and probing depths. Mobile teeth were extracted.
Ultimately surgery wasn't necessary.
The patient experienced multiple carious lesions and large
amounts of plaque deposits that could be attributed in
part to the negligence of oral hygiene or due to her reluc-
tance to brush because of the bleeding gingivae. Mac-
roglossia – which is in turn could be reactive to
continuous use of AED's during years of development or
secondary to diabetes mellitus – might complicate oral
hygiene methods especially posteriorly.
Patients placed on AED's therapy should be referred to a
dentist/periodontist for plaque control instructions and
education, professional scaling or gingival curettage and
regular follow-up visits.
To restore partial edentulism it is generally preferable to
place fixed prosthesis rather than removable appliance
because of the possibility for removable appliances to
become dislodged during seizure attacks. It is also advised
to use metallic prosthesis as it is less liable to fracture.
Costs of treatment also should be considered if prostheses
are expected to be replaced because of the repetitive frac-
tures. Ultimately, for every case a treatment plan should
be designed individually [25].
Fillings can be done safely, provided that the dentist is
aware of the level of seizure control and intellectual activ-
ity of the patient as well as the difficulty to apply local and
general anesthesia. Coordination with the physician/neu-
rologist is important in this regard.
Conclusion
The clinical findings in LGS could be associated with the
syndrome itself or with the effects of pharmacological
treatment, and it might include facial deformities, perio-
dontitis and gingival swellings. Interdisciplinary treat-
ment of these patients is fundamental and oral attention
is of outstanding importance.
Non-surgical periodontal therapy was effective in control-
ling periodontal disease in the reported case, but preven-
tion of periodontal and dental diseases is preferable for
this high-risk group of patients.
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